SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Vickers Andrew J.) "

Sökning: WFRF:(Vickers Andrew J.)

  • Resultat 61-70 av 78
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  • Steuber, Thomas, et al. (författare)
  • Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer
  • 2007
  • Ingår i: Clinical Chemistry. - : Oxford University Press (OUP). - 0009-9147 .- 1530-8561. ; 53:2, s. 233-240
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) and prostate-specific antigen (PSA) with prostate cancers of unfavorable prognosis. Methods: We retrospectively measured total PSA (tPSA), free PSA (fPSA), and total hK2 (thK2) in preoperative serum samples from 867 men [and assessed free hK2 (fhK2) measured in 577 of these men] treated with radical prostatectomy for clinically localized prostate cancer. Associations between biomarker concentrations and extracapsular extension, seminal vesicle invasion, and biochemical recurrence (BCR) were evaluated. A subset of patients with PSA <= 10 mu g/L, the group most commonly seen in clinical practice in the US, was analyzed. Results: thK2 was the strongest predictor of extracapsular extension and seminal vesicle invasion (areas under the ROC curve [AUC], 0.662 and 0.719, respectively), followed by tPSA (AUC, 0.654 and 0.663). All biomarkers were significant predictors of BCR. hK2 forms, but not PSA forms, remained highly significant for predicting BCR in the low-PSA group. Combining tPSA, fPSA, and thK2 in a multivariable model improved prediction compared with any biomarker used individually (AUC, 0.711, 0.755, and 0.752 for this combination predicting extracapsular extension, seminal vesicle invasion, and BCR, respectively; P < 0.001 for all). Conclusions: Increased concentrations of hK2 in the blood are significantly associated with unfavorable features of prostate cancer, and thK2 is predictive of locally advanced and recurrent cancer in patients with PSA <= <= 10 mu g/L. Independent of tPSA and fPSA, hK2 predicts unfavorable prognosis. (c) 2007 American Association for Clinical Chemistry
  •  
62.
  • Tin, Amy L., et al. (författare)
  • Pain as bad as you can imagine or extremely severe pain? A randomized controlled trial comparing two pain scale anchors
  • 2023
  • Ingår i: Journal of Patient-Reported Outcomes. - 2509-8020. ; 7:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: A common method of pain assessment is the numerical rating scale, where patients are asked to rate their pain on a scale from 0 to 10, where 0 is “no pain” and 10 is “pain as bad as you can imagine”. We hypothesize such language is suboptimal as it involves a test of a cognitive skill, imagination, in the assessment of symptom severity. Methods: We used a large-scale online research registry, ResearchMatch, to conduct a randomized controlled trial to compare the distributions of pain scores of two different pain scale anchors. We recruited adults located in the United States who reported a chronic pain problem (> 3 months) and were currently in pain. Participants were randomized in a 1:1 ratio to receive pain assessment based on a modified Brief Pain Inventory (BPI), where the anchor for a score of 10 was either “extremely severe pain”, or the original BPI, with the anchor “pain as bad as you can imagine”. Participants in both groups also answered additional questions about pain, other symptomatology and creativity. Results: Data were obtained from 405 participants for the modified and 424 for the original BPI. Distribution of responses to pain questions were similar between groups (all p-values ≥ 0.12). We did not see evidence that the relationship between pain score and the anchor text differed based on self-perceived creativity (all interaction p-values ≥ 0.2). However, in the key analysis, correlations between current pain assessments and known correlates (fatigue, anxiety, depression, current pain compared to a typical day, pain compared to other people) were stronger for “extreme” vs. “imaginable” anchor text (p = 0.005). Conclusion: Pain rating scales should utilize the modified anchor text “extremely severe pain” instead of “pain as bad as you can imagine”. Further research should explore the effects of anchors for other symptoms.
  •  
63.
  • Ulmert, David, et al. (författare)
  • Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
  • 2008
  • Ingår i: Journal of Clinical Oncology. - 1527-7755. ; 26:6, s. 835-841
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose We tested whether total prostate-specific antigen velocity (tPSAv) improves accuracy of a model using PSA level to predict long-term risk of prostate cancer diagnosis. Methods During 1974 to 1986 in a preventive medicine study in Sweden, 5,722 men aged <= 50 gave two blood samples about 6 years apart. We measured free (fPSA) and total PSA (tPSA) in archived plasma samples from 4,907 participants. Prostate cancer was subsequently diagnosed in 443 (9%) men. Cox proportional hazards regression was used to evaluate tPSA and tPSAv as predictors of prostate cancer. Predictive accuracy was assessed by the concordance index. Results The median time from second blood draw to cancer diagnosis was 16 years; median follow-up for men without prostate cancer was 21 years. In univariate models, tPSA level at second assessment and tPSAv between first and second assessments were associated with prostate cancer (both P < .001). tPSAv was highly correlated with tPSA level (r = 0.93). Twenty-year probabilities of cancer for men at 50th, 90th, and 95th percentile of tPSA and tPSAv were 10.6%, 17.1%, and 21.2% for tPSA, and 9.1%, 11.8%, and 14.1% for tPSAv, respectively. The concordance index for tPSA level was 0.771. Adding tPSAv, fPSA, % fPSA or velocities of fPSA and % fPSA did not importantly increase accuracy of tPSA to predict prostate cancer. Results were unchanged if the analysis was restricted to patients with advanced cancer at diagnosis. Conclusion Although PSA velocity is significantly increased in men with prostate cancer up to two decades before diagnosis, it does not aid long-term prediction of prostate cancer.
  •  
64.
  • Ulmert, David, et al. (författare)
  • Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
  • 2008
  • Ingår i: BMC Medicine. - : Springer Science and Business Media LLC. - 1741-7015. ; 6
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Based on a large, representative unscreened cohort from Malmo, Sweden, we have recently reported that a single prostate-specific antigen (PSA) measurement at or before age 50 is a strong predictor of prostate cancer occurring up to 25 years subsequently. We aimed to determine whether this association holds for advanced cancers, defined as clinical stage T3 or higher, or skeletal metastasis at the time of the cancer diagnosis. Methods: In 1974-1986 blood samples were obtained from a cohort of 21,277 men aged up to 50. Through 1999, 498 men were diagnosed with prostate cancer, and of these 161 had locally advanced or metastatic prostate cancers. Three controls, matched for age and date of venipuncture, were selected for each case. Conditional logistic regression was used to test associations between molecular markers and advanced cancer. Results: Median time from venipuncture to diagnosis was 17 years. Levels of all PSA forms and hK2 were associated with case status. Total PSA was a strong and statistically significant predictor of subsequent advanced cancer ( area under the curve 0.791; p < 0.0005). Two-thirds of the advanced cancer cases occurred in men with the top 20% of PSA levels (0.9 ng/ml or higher). Conclusion: A single PSA test taken at or before age 50 is a very strong predictor of advanced prostate cancer diagnosed up to 25 years later. This suggests the possibility of using an early PSA test to risk-stratify patients so that men at highest risk are the focus of the most intensive screening efforts.
  •  
65.
  • Ulmert, David, et al. (författare)
  • Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
  • 2012
  • Ingår i: Clinical Chemistry and Laboratory Medicine. - : Walter de Gruyter GmbH. - 1434-6621 .- 1437-4331. ; 50:11, s. 1993-1998
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The utility of conventional prostate-specifi c antigen (PSA) measurements in blood for monitoring rapid responses to treatment for prostate cancer is limited because of its slow elimination rate. Prior studies have shown that free PSA (fPSA), intact PSA (iPSA) and human kallikrein-related peptidase 2 (hK2) are eliminated more rapidly after radical prostatectomy. In contrast, all three markers have similarly slow elimination rates after castration induced by gonadotropin-releasing hormone (GnRH) agonists, possibly due to the slow onset of castration. Therefore, we assessed elimination rates of tPSA, fPSA, iPSA and hK2 after rapid induction of castration with degarelix (Firmagon (R)), a novel GnRH antagonist. Methods: This study included 24 patients treated with degarelix. Blood was taken at 1, 3, 7, 14, 21 and 28 days after injection of degarelix. Free and total PSA were measured with a commercial dual-label assay, and with inhouse research assays of intact PSA and hK2. Results: Median (interquartile range, IQR) tPSA at baseline was 23.4 (15.8, 59.8). Twenty-two patients (92%) reached castrate levels of testosterone within 24 h of degarelix initiation, and all patients did so within 72 h. All kallikrein forms declined in an exponential fashion after degarelix administration. The median time to 50% reduction in biomarker level was 8-9 days for tPSA or complexed PSA vs. 2-4 days for hK2, iPSA and fPSA. The percentage eliminated at day 3 and day 7 was significantly higher for hK2, iPSA and fPSA than for tPSA (all p<0.02), while tPSA and complexed PSA were similar. Conclusions: The rapid decline of fPSA, iPSA and hK2 after fast induction of castration with degarelix is similar to that reported after prostatectomy and offers a novel, informative method to monitor rapid onset of therapeutic action targeting signaling of the androgen receptor.
  •  
66.
  •  
67.
  • Vertosick, Emily A, et al. (författare)
  • Prespecified Four Kallikrein Marker Model (4Kscore) at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population-Based Cohort of Asymptomatic Men Followed for 20 Years.
  • 2020
  • Ingår i: Journal of Urology. - : Lippincott Williams & Wilkins. - 0022-5347 .- 1527-3792. ; 204:2, s. 281-288
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: A prespecified statistical model based on 4 kallikrein markers in blood, commercially available as the 4Kscore®, has been shown to accurately detect high grade (greater than Grade Group 2) prostate cancer in men with moderately elevated prostate specific antigen. We assessed whether the model predicted prostate cancer metastasis or death in men not subject to prostate specific antigen screening.Materials and Methods: The cohort includes 43,692 unscreened prostate cancer-free men from a Swedish population based cohort with low rates of prostate specific antigen screening (Västerbotten Intervention Project). Using cryopreserved blood collected at ages 50 and 60 years from men in this cohort we analyzed the association between prostate specific antigen and other kallikrein marker levels in blood and risk of prostate cancer metastasis or death.Results: There were 308 with metastases and 172 prostate cancer deaths. Baseline prostate specific antigen was strongly associated with 20-year risk of prostate cancer death (c-index at age 50, 0.859, 95% CI 0.799–0.916; age 60, 0.840, 95% CI 0.799–0.878). Men 60 years old with prostate specific antigen below median (less than 1.2 ng/ml) had 0.4% risk of prostate cancer death at 20 years. Among men with moderately elevated prostate specific antigen (2.0 ng/ml or greater) the 4Kscore markedly improved discrimination (c-index 0.767 vs 0.828 and 0.774 vs 0.862 in men age 50 and 60, respectively). Long-term risk of prostate cancer death or metastasis in men with low 4Kscores was very low.Conclusions: Screening should focus on men in top prostate specific antigen quartile at age 60 years. Men with elevated prostate specific antigen but a low 4Kscore can safely be monitored with repeated blood markers in place of immediate biopsy.
  •  
68.
  • Vertosick, Emily A., et al. (författare)
  • Reply by Authors
  • 2020
  • Ingår i: The Journal of urology. - 1527-3792. ; 204:2, s. 287-288
  • Tidskriftsartikel (refereegranskat)
  •  
69.
  • Vickers, Andrew, et al. (författare)
  • Individualized Estimation of the Benefit of Radical Prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial
  • 2012
  • Ingår i: European Urology. - : Elsevier BV. - 0302-2838 .- 1873-7560. ; 62:2, s. 204-209
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Although there is randomized evidence that radical prostatectomy improves survival, there are few data on how benefit varies by baseline risk. Objective: We aimed to create a statistical model to calculate the decrease in risk of death associated with surgery for an individual patient, using stage, grade, prostate-specific antigen, and age as predictors. Design, setting, and participants: A total of 695 men with T1 or T2 prostate cancer participated in the Scandinavian Prostate Cancer Group 4 trial (SPCG-4). Intervention: Patients in SPCG-4 were randomized to radical prostatectomy or conservative management. Outcome measurements and statistical analysis: Competing risk models were created separately for the radical prostatectomy and the watchful waiting group, with the difference between model predictions constituting the estimated benefit for an individual patient. Results and limitations: Individualized predictions of surgery benefit varied widely depending on age and tumor characteristics. At 65 yr of age, the absolute 10-yr risk reduction in prostate cancer mortality attributable to radical prostatectomy ranged from 4.5% to 17.2% for low-versus high-risk patients. Little expected benefit was associated with surgery much beyond age 70. Only about a quarter of men had an individualized benefit within even 50% of the mean. A limitation is that estimates from SPCG-4 have to be applied cautiously to contemporary patients. Conclusions: Our model suggests that it is hard to justify surgery in patients with Gleason 6, T1 disease or in those patients much above 70 yr of age. Conversely, surgery seems unequivocally of benefit for patients who have Gleason 8, or Gleason 7, stage T2. For patients with Gleason 6 T2 and Gleason 7 T1, treatment is more of a judgment call, depending on patient preference and other clinical findings, such as the number of positive biopsy cores and comorbidities. 
  •  
70.
  • Vickers, Andrew J, et al. (författare)
  • Eight Misconceptions about Prostate-Specific Antigen
  • 2024
  • Ingår i: Clinical Chemistry. - 0009-9147. ; 70:1, s. 13-16
  • Tidskriftsartikel (refereegranskat)abstract
    • Prostate-specific antigen (PSA) was discovered in the 1970s, with assays to detect PSA in blood approved by the US Food and Drug Administration in 1986. Almost from the very beginning, its role as a prostate cancer marker has been severely misunderstood. One of the most well-known misconceptions is that prostate cancer detectable by elevated PSA in asymptomatic men requires treatment, irrespective of stage and grade. Accordingly, when PSA testing to detect prostate cancer began in the United States in the late 1980s and early 1990s, most men with elevated PSA were biopsied and nearly all cancers detected were treated. It is estimated that in its first 20 years of use, PSA screening led to >1 million Americans suffering harm from radiotherapy or surgery to treat a cancer that would never become apparent before they died of another cause (1).More than 35 years later, PSA continues to be misunderstood. Here, we try to correct 8 common contemporary misconceptions about PSA. In brief, PSA may have a bad reputation, but it has remarkable properties—when used correctly—that make the clinical biochemistry of prostate cancer the envy of all other solid tumors.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 78
Typ av publikation
tidskriftsartikel (72)
forskningsöversikt (5)
Typ av innehåll
refereegranskat (76)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Lilja, Hans (60)
Ulmert, David (17)
Bjartell, Anders (15)
Roobol, Monique J (12)
Pettersson, Kim (10)
Vertosick, Emily A (8)
visa fler...
Björk, Thomas (7)
Stattin, Pär (7)
Hugosson, Jonas, 195 ... (7)
Carlsson, Sigrid, 19 ... (7)
Manjer, Jonas (6)
Carlsson, Sigrid V (5)
Becker, Charlotte (5)
Johansson, Robert (4)
Nilsson, Peter (4)
Häggström, Christel (4)
Berglund, Göran (4)
Mucci, Lorelei A (3)
Kibel, Adam S (3)
Hallmans, Göran, 194 ... (3)
Halldén, Christer (3)
Scher, Howard I. (3)
Sjoberg, Daniel (3)
Abrahamsson, Per-And ... (2)
Brown, R. (2)
Durand, M (2)
Li, C. (2)
Montorsi, Francesco (2)
Jones, S. (2)
Barry, J (2)
Haese, Alexander (2)
Huland, Hartwig (2)
Graefen, Markus (2)
Bill-Axelson, Anna (2)
Rossi, S (2)
Zambon, M (2)
Silva, R (2)
Ribeiro, R (2)
Gomes, J (2)
Torres, A (2)
Patel, M (2)
Neal, David E (2)
Haiman, Christopher ... (2)
Sørensen, Karina D (2)
Borre, Michael (2)
Hallmans, Göran (2)
Lee, C. (2)
Offit, Kenneth (2)
Jiborn, Thomas (2)
Auvinen, Anssi (2)
visa färre...
Lärosäte
Lunds universitet (65)
Göteborgs universitet (17)
Uppsala universitet (8)
Umeå universitet (7)
Karolinska Institutet (5)
Högskolan i Halmstad (1)
visa fler...
Stockholms universitet (1)
Örebro universitet (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (78)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (74)
Naturvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy